George Harrison Talbot
Founder bij Talbot Advisors LLC
Profiel
George Harrison Talbot is the founder of Kalidex Pharmaceuticals, Inc. (founded in 2010), Talbot Advisors LLC (founded in 2000), and AN2 Therapeutics, Inc. (founded in 2017).
At Kalidex Pharmaceuticals, he held the title of Senior Clinical Advisor from 2010 to 2013.
At Talbot Advisors LLC, he held the title of Principal.
At AN2 Therapeutics, Inc., he held the title of Director.
Dr. Talbot's former jobs include Co-Chairman at Foundation for the National Institutes of Health, Inc., Independent Director at Nabriva Therapeutics Plc (2017-2021), Chief Medical Officer & Executive Vice President at Cerexa, Inc. (2006-2007), Member-Supervisory Board at Nabriva Therapeutics GmbH (2009-2017), and Member at Infectious Diseases Society of America.
Dr. Talbot's education includes an undergraduate degree from Wesleyan University and a doctorate from Yale School of Medicine.
Actieve functies van George Harrison Talbot
| Bedrijven | Functie | Begin |
|---|---|---|
| Talbot Advisors LLC | Founder | 01-01-2000 |
Eerdere bekende functies van George Harrison Talbot
| Bedrijven | Functie | Einde |
|---|---|---|
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 28-07-2021 |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Director/Board Member | 23-06-2017 |
Kalidex Pharmaceuticals, Inc.
 Kalidex Pharmaceuticals, Inc. BiotechnologyHealth Technology Kalidex Pharmaceuticals, Inc. develops antibiotics for the treatment of serious infections. Its lead development candidate KPI-10 is a next-generation fluoroquinolone against a range of important gram-negative and gram-positive pathogens including multi-drug resistant strains and isolates resistant to currently available fluoroquinolones. The company was founded in 2010 by James Ge, Vernocn Jiang and George H. Talbot and is headquartered in Menlo Park, CA. | Founder | 15-05-2013 |
Cerexa, Inc.
 Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Chief Tech/Sci/R&D Officer | 02-01-2007 |
| AN2 THERAPEUTICS, INC. | Founder | - |
Opleiding van George Harrison Talbot
| Wesleyan University | Undergraduate Degree |
| Yale School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NABRIVA THERAPEUTICS PLC | Health Technology |
| AN2 THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Health Technology |
Kalidex Pharmaceuticals, Inc.
Kalidex Pharmaceuticals, Inc. BiotechnologyHealth Technology Kalidex Pharmaceuticals, Inc. develops antibiotics for the treatment of serious infections. Its lead development candidate KPI-10 is a next-generation fluoroquinolone against a range of important gram-negative and gram-positive pathogens including multi-drug resistant strains and isolates resistant to currently available fluoroquinolones. The company was founded in 2010 by James Ge, Vernocn Jiang and George H. Talbot and is headquartered in Menlo Park, CA. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
Infectious Diseases Society of America
 Infectious Diseases Society of America Miscellaneous Commercial ServicesCommercial Services The Infectious Diseases Society of America is a non-profit company that provides clinical practice guidelines development and guideline panelists for infectious diseases. The company is based in Arlington, VA and has subsidiaries in the United States. The company specializes in antimicrobial stewardship and have established Antimicrobial Stewardship Centers of Excellence. The CEO of the company is Christopher Busky. | Commercial Services |
Foundation for the National Institutes of Health, Inc.
 Foundation for the National Institutes of Health, Inc. Miscellaneous Commercial ServicesCommercial Services Foundation for the National Institutes of Health, Inc. provides healthcare services. It offers services to public health through scientific discovery, translational research and dissemination of research results through public-private partnerships. The organization was founded in 1996 and is headquartered in Bethesda, MD | Commercial Services |
| Talbot Advisors LLC |
